Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

NCT00294164 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00294164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00294164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Lead sponsor
EMD Serono
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2001
Completion date
May 31, 2002
Enrollment
245 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus infections, human immunodeficiency virus-associated adipose redistribution syndrome (hars)